StudyRareStudyRare

Carnitine-acylcarnitine translocase deficiency (CACT)

Log in to star

Last updated Nov 4, 2026

Log in to add personal notes on this page.

A neonate presents in the first 48 hours of life with seizures, cardiac arrhythmia, hypoketotic hypoglycemia, and hyperammonemia. Acylcarnitine profile shows markedly elevated C16, C18, and C18:1 with low free carnitine.

AR; SLC25A20 (carnitine-acylcarnitine translocase, inner mitochondrial membrane). Biallelic loss-of-function variants stop long-chain acylcarnitines from entering the matrix.

Carnitine-acylcarnitine translocase (CACT) sits in the inner mitochondrial membrane and moves the long-chain acylcarnitines made by CPT1 into the matrix in exchange for free carnitine; CPT2 then turns them back into acyl-CoA for beta-oxidation.

With CACT lost, long-chain fatty acid oxidation cannot proceed. Heart, skeletal muscle, and liver, the tissues that depend on it during stress or fasting, turn to glycogen and protein instead. As those run out, hypoglycemia, hyperammonemia, and rhabdomyolysis from protein breakdown follow. The severe neonatal form begins around day 2 of life, often before the screening result, with arrhythmia as the leading cardiac feature; cardiac arrest from ventricular tachycardia is the most common cause of death. Chronic hyperammonemia is a major factor in neurologic outcome.

Homozygosity for the splice variant c.199-10T>G (the most common variant, frequent in East and Southeast Asian families), the frameshift c.270delC, or the missense p.Gln238Arg gives the severe neonatal form; homozygous missense p.Gly28Cys gives a milder or later-onset form. The acylcarnitine pattern is the same as in CPT2 deficiency, so gene testing or enzyme studies are needed to tell them apart.

carnitine palmitoyltransferase 1ACPT1A; with long-chain acyl-CoA;outer mitochondrial membrane; therate-limiting stepCPT1A deficiencycarnitine-acylcarnitinetranslocaseSLC25A20; across the innermembrane, in exchange for freecarnitineCACT deficiencycarnitine palmitoyltransferase 2CPT2; inner membrane, matrix sideCPT2 deficiencycarnitine in the celllong-chainacylcarnitineacylcarnitine in thematrixlong-chain acyl-CoA +free carnitine
Excerpt from the carnitine shuttle. See the full pathway.

Part of the carnitine shuttle.

Carnitine shuttle, the step that crosses the inner mitochondrial membrane.

long-chain acyl-CoA → CPT1A → long-chain acylcarnitine → carnitine-acylcarnitine translocase, inner mitochondrial membrane (the block) → acylcarnitine in the matrix, exchanged for free carnitine → CPT2 → long-chain acyl-CoA → beta-oxidation

  • Accumulates: long-chain acylcarnitines, measured as C16, C16:1, C18, and C18:1, with low free carnitine (C0).
  • Missing: long-chain fat oxidation in the matrix, so glycogen and protein are spent and hypoglycemia, hyperammonemia, and rhabdomyolysis follow.
  • Workbook: 5.D. Disorders of the carnitine shuttle system
  • Severe neonatal-lethal phenotype is the rule: cardiomyopathy, arrhythmia (often ventricular), hyperammonemia, hypoketotic hypoglycemia, liver failure
  • Milder later-onset forms exist but are rare
  • Acylcarnitine profile resembles CPT2 (elevated long-chain species) and is not distinguishable on NBS alone; genetic testing confirms
  • Newborn screening (RUSP) acylcarnitine profile: elevated long-chain species (C16, C18, C18:1) with low free carnitine (C0)
  • Profile is indistinguishable from CPT2 deficiency; the two cannot be separated biochemically
  • Confirmatory SLC25A20 molecular testing distinguishes CACT from CPT2 (fibroblast/leukocyte enzyme studies can supplement)
  • Avoid fasting; aggressive emergency IV glucose
  • MCT-rich, low long-chain-fat diet
  • Carnitine supplementation was debated because of cardiotoxicity in mouse models, but experience in people with CACT deficiency shows no cardiotoxicity, and carnitine helps export toxic long-chain acyl-CoA as acylcarnitines
  • Most severe cases do not survive infancy despite treatment

"CACT carts the cargo across." The translocase shuttles long-chain acylcarnitines across the inner mitochondrial membrane. When the cart breaks, fatty acids cannot reach the matrix to be oxidized; the phenotype is severe because every long-chain fatty acid is blocked.

Same biomarker as CPT2, different prognosis. Both CACT and CPT2 elevate C16, C18, and C18:1, but CACT is almost uniformly lethal in the neonatal period whereas CPT2 has a spectrum.

Reference Links